Indefinite Delivery Contract SPE2DX15D9217

The federal contract IDV award SPE2DX15D9217 is a single-award Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The $499,999,999 IDC, valid through November 2026, was awarded by the Defense Logistics Agency (DLA) under the SPE2DB program to provide the Department of Defense (DoD) with a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. The contract covers various product categories such as injections, tablets, creams, auto-injectors, and specialty medications, positioning DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain. Through this IDC, the DLA can issue firm fixed-price delivery orders to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers nationwide.

The scope of the contracted products and services aligns with DMS Pharmaceutical Group's expertise as a pharmaceutical wholesaler, enabling the company to leverage its status as a woman-owned small business to secure direct federal awards across multiple medical domains. The IDC allows the DLA to efficiently procure a diverse array of pharmaceutical items, including specialized medications such as Xolair, Trikafta, Keytruda, Botox, and Nucala, to meet the diverse medical supply requirements of the DoD healthcare system.